Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AmpliMed
Patient enrollment begins for phase I/II trial of Amplimexon plus dacarbazine
August 10th, 2005
AmpliMed announced that the company has begun to enroll patients in a new clinical trial that will evaluate its lead candidate, Amplimexon (imexon inj.) in combination with the drug dacarbazine (DTIC) in patients with unresectable Stage III or Stage IV malignant melanoma who have not been previously treated with chemotherapy for their metastatic disease. Melanoma is the most serious form of skin cancer and, during the past 10 years, the number of cases has increased more rapidly than that of any other cancer. Dacarbazine (DTIC) is a chemotherapeutic agent that interferes with the growth of cancer cells. It is one of only two drugs approved for sale...
Source: Biotech Week (2005-08-10)
|
